Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flow from operating activities
Net (loss) income	$ (21,471)	$ 101,836
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Stock-based compensation expense	7,615	5,230
Depreciation	2,588	2,161
Impairment charge on leased facility	2,776
Amortization of premiums and discounts on marketable securities	(4,395)	(25)
Loss on disposal of fixed assets	286	124
Changes in operating assets and liabilities:
Accounts receivable	78,448
Related party collaboration receivable	1,792	(3,093)
Prepaid expenses and other current assets	(1,980)	(686)
Operating lease, right-of-use asset	2,432	957
Accounts payable	1,001	(907)
Accrued expenses	(6,550)	1,296
Operating lease liabilities	(104)	(1,385)
Deferred revenue	(35,251)	17,222
Net cash provided by operating activities	27,187	122,730
Cash flow from investing activities
Purchases of property and equipment	(3,108)	(1,719)
Purchases of marketable securities	(293,859)	(28,453)
Proceeds from sales and maturities of marketable securities	164,959	20,000
Net cash used in investing activities	(132,008)	(10,172)
Cash flow from financing activities
Proceeds from the exercise of stock options	168	1,414
Proceeds from the issuance of common stock in connection with the underwritten public offering	93,473
Proceeds from the issuance of common stock in connection with the 2023 Novartis Stock Purchase Agreement	19,305
Proceeds from the issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement		31,121
Proceeds from the purchase of common stock under ESPP	481	319
Net cash provided by financing activities	113,427	32,854
Net increase in cash, cash equivalents, and restricted cash	8,606	145,412
Cash, cash equivalents, and restricted cash, beginning of period	70,395	100,474
Cash, cash equivalents, and restricted cash, end of period	79,001	245,886
Supplemental disclosure of cash and non-cash activities
Capital expenditures incurred but not yet paid		$ 52
Operating lease right-of-use asset obtained in exchange for operating lease liability	$ 26,751